The effects of JARID1B siRNA on proliferation and apoptosis in HL-60 cell.
- Author:
Xu-dong MA
1
;
Hui-dan HAN
;
Yi-qun HUANG
;
Yong ZOU
Author Information
- Publication Type:Journal Article
- MeSH: Apoptosis; Caspase 3; metabolism; Caspase 9; metabolism; Cell Proliferation; Cyclin-Dependent Kinase Inhibitor p27; metabolism; Gene Expression Regulation, Leukemic; Gene Targeting; HL-60 Cells; Histones; metabolism; Humans; Jumonji Domain-Containing Histone Demethylases; genetics; Leukemia; genetics; Methylation; Nuclear Proteins; genetics; Proto-Oncogene Proteins c-bcl-2; metabolism; Proto-Oncogene Proteins c-myc; metabolism; RNA Interference; RNA, Messenger; genetics; RNA, Small Interfering; Repressor Proteins; genetics
- From: Chinese Journal of Hematology 2012;33(5):392-396
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo study the effect of small interfering RNA(siRNA) targeting JARID1B gene on the proliferation and apoptosis in HL-60 acute promyelocytic leukemia cell line, and to explore its mechanisms.
METHODSThe JARID1B siRNA was transfected into HL-60 cells using Lipofectamine(TM) 2000(Lipo) vector. The proliferation inhibition by siRNA targeting JARID1B was detected by MTT, cells apoptosis by flow cytometry, the mRNA expression of JARID1B by RT-PCR, the protein expression of JARID1B, Bcl-2, procaspase-9, procaspase-3, c-myc and P27 and histone methylated H3K4 by Western blot.
RESULTSsiRNA targeting JARID1B upregulated histone methylated H3K4 level, inhibited the proliferation of HL-60 cells, and induced the cells apoptosis. After transfection of siRNA targeting JARID1B at 0, 30, 60, 120 nmmol/L for 24 hours, the apoptotic rate were (11.0 ± 3.6)%, (35.2 ± 5.1)%, (52.7 ± 3.8)%, and (62.0 ± 5.7)% respectively (F = 70.27, P < 0.01). The protein expression of P27 was upregulated, and Bcl-2, procaspase-9, procaspase-3, c-myc was down regulated.
CONCLUSIONSJARID1B siRNA upregulates histone methylated H3K4. It reduces HL-60 cells proliferation and apoptosis by up regulating the p27 expression and down regulating the Bcl-2, procaspase-9, procaspase-3, c-myc expression. It might be a new therapeutic targeting for human leukemia.
